Abstracts tagged "Autoinflammatory diseases"

Abstract Number: 2576 • ACR Convergence 2025
Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
Alfonso Sucerquia¹, Jose Forero², Juan Alzate¹, Adrienne Poon³, Gary Firestein⁴, Larry Moreland⁵, Andres Cadena⁶, Jose Lara⁶, Octavio pizarro⁶, Jesus Godoy⁶, Liliana Encinales⁷, David Boyle⁸, Evelyn Mendoza⁹, Carlos Herrera¹⁰ and Aileen Chang³, ¹The George Washington University, Arlington, ²The George Washington University, Arlington, VA, ³The George Washington University, Washington, ⁴University of California, San Diego, San Diego, CA, ⁵University of Colorado, Denver, CO, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷Allied Research Society, Barranquilla, Colombia, ⁸University of California, San Diego, San Diego, ⁹Universidad Libre de Barranquilla, Barranquilla, Colombia, ¹⁰The George Washington University, Alexandria
Background/Purpose: The MARCH study evaluates the efficacy of methotrexate monotherapy in patients with chikungunya-associated arthritis and aims to elucidate its pathologic mechanism via cytokine analysis.…
Abstract Number: 2043 • ACR Convergence 2025
Renal Outcomes of Long-term Canakinumab in Patients with Adult Familial Mediterranean Fever (FMF) and Biopsy-Confirmed AA Amyloidosis
Büşra Fırlatan Yazgan¹, Gözde Sevgi Kart bayram¹, Buğu Bulat¹, Levent Kılıç¹, Tolga Yildirim², Umut Kalyoncu¹, Şule Apraş Bilgen¹, Ali İhsan Ertenli¹, Seref Rahmi Yilmaz² and Omer Karadag³, ¹Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²Division of Nephrology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Background/Purpose: Canakinumab, an interleukin-1β inhibitor, has demonstrated efficacy in treating colchicine-resistant/intolerant familial Mediterranean fever (FMF). This study aims to assess the efficacy and safety of…
Abstract Number: 1651 • ACR Convergence 2025
Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations
Mary Maclean¹, Sabrina Helmold Hait², Cindy Phung³, Deborah Stone⁴, Sophie georgin-Lavialle⁵, Scott Canna⁶, Carl Esperanzate⁷, Amanda Ombrello⁸, Daniel Kastner⁹, Ivona Aksentijevich¹⁰ and Massimo Gadina¹¹, ¹NIH-NIAMS, Rockville, MD, ²NIAMS/NIH, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS), Bethesda, MD, ⁴NIH, Bethesda, MD, ⁵Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷National Human Genome research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, ⁸National Institutes of Health, Rockville, MD, ⁹National Human Genome Research Institute, Bethesda, MD, ¹⁰¹⁰⁰, Bethesda, MD, ¹¹National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD
Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease associated with biallelic pathogenic variants in the MEFV gene encoding the myeloid-restricted inflammasome sensor pyrin. The…
Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Guishan Liu¹, Jingyuan zhang², jin Xu², JiaYuan Dai² and Min Shen², ¹Peking union medical college hospital, Beijing, Beijing, China (People's Republic), ²Peking union medical college hospital, Beijing, China (People's Republic)
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…
Abstract Number: 0257 • ACR Convergence 2025
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Bruce E. Sands¹, Remo Panaccione², Silvio Danese³, Julián Panés⁴, Tadakazu Hisamatsu⁵, Geert D’Haens⁶, Rian Van Rampelbergh⁷, Mobolaji Olurinde⁸, Jacqueline Yee⁸, Karissa Lozenski⁹, Thomas Baker⁸, Shadi Yarandi⁸, Matthew Germinaro⁸, Marion L. Vetter⁸, Hewei Li⁸, Mauricio Rosas Ballina¹⁰, Jessica R. Allegretti¹¹, Anita Afzali¹² and David T. Rubin¹³, ¹Icahn School of Medicine at Mount Sinai, New York, NY, USA, NY, ²University of Calgary, Calgary, AB, Canada, AB, Canada, ³Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy, Milano, Italy, ⁴Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, Barcelona, Spain, ⁵Kyorin University School of Medicine, Tokyo, Japan, Tokyo, Japan, ⁶Amsterdam University Medical Centers, Amsterdam, The Netherlands, D’Haens, Swaziland, ⁷Johnson & Johnson, Antwerp, Belgium, Antwerp, Belgium, ⁸Johnson & Johnson, Spring House, PA, USA, PA, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Actelion Research & Development, Allschwil, Switzerland, Allschwil, Switzerland, ¹¹Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, MA, ¹²University of Cincinnati, College of Medicine, Cincinnati, OH, USA, OH, ¹³University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, IL
Background/Purpose: Guselkumab (GUS), a dual-acting interleukin (IL)-23 inhibitor that potently neutralizes IL-23 and binds to CD64 (a receptor on cells that produce IL-23), is currently…
Abstract Number: 2428 • ACR Convergence 2025
Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Shae Chambers¹, Aretha On², Xiwei Yang², Lais Lopes Almeida Gomes¹, Touraj Khosravi-Hafshejani³, Hammad Ali³, Rui Feng⁴ and Victoria Werth¹, ¹University of Pennsylvania, Philadelphia, PA, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease marked by skin lesions that can vary in appearance and severity. Subacute cutaneous erythematosus (SCLE),…
Abstract Number: 2037 • ACR Convergence 2025
The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution
Manuel Carpio Tumba¹, Tingyan He², Jun Wang³, Elizabeth Kairis¹, Kyr Goyette¹, Akuti Kethri¹, Urekha Karri⁴, Atif Towheed¹, Jun Yang⁵, Qing Zhou⁶ and Daniella Schwartz¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Shenzhen Children's Hospital, Shenzhen, China (People's Republic), ³Zhejiang University School of Medicine, Zhejiang, China (People's Republic), ⁴School of public health, Pittsburgh, PA, ⁵Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, ⁵¹⁸¹⁰⁰, China., Shenzhen, China (People's Republic), ⁶Zhejiang University School of Medicine, Hangzhou, China (People's Republic)
Background/Purpose: Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disease caused by loss-of-function (LOF) mutations in TNFAIP3. HA20 was initially described as an early-onset form…
Abstract Number: 1625 • ACR Convergence 2025
Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
Ashika Ajitumar¹, Eric Robbins², Yusuf Mastoor² and Marcela ferrada³, ¹University of Maryland, baltimore, MD, ²University of Maryland, baltimore, ³University of Maryland, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disease marked by episodic inflammation of cartilaginous tissues. A major challenge in its clinical management is the…
Abstract Number: 1153 • ACR Convergence 2025
New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Michael Cargill² and Gurjit Kaeley³, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
Abstract Number: 0255 • ACR Convergence 2025
Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis
Justin Riley Lam¹, Emmanuel Otabor², Laith Alomari², Esteban Kosak Lopez², Maxim Barnett² and Shahrzad Abdollahi³, ¹Albert Einstein Medical Center, Philadelphia, PA, ²Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ³Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Cannabis use has increased substantially in the past decades, with legalization expanding across the U.S. Despite its known therapeutic potential, the immunomodulatory effects of…
Abstract Number: 2329 • ACR Convergence 2025
Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Sehneet Grewal, Rubab Rizwan, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, Poughkeepsie, NY
Background/Purpose: Psoriasis, a chronic inflammatory skin condition, is increasingly linked to systemic cardiovascular risks. Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with…
Abstract Number: 2032 • ACR Convergence 2025
Validation of systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS 10) in adult patients with Still’s Disease
Georgia-Savina Moysidou¹, Spyridon Katechis², Stéphane Mitrovic³ and Bruno Fautrel⁴, ¹Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Athens, Greece, ²National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Paris, France, ⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Recent EULAR/PReS recommendations have acknowledged the lack of unique and consensual tool to quantify disease activity in Still’s disease (SD). The systemic Juvenile Arthritis…
Abstract Number: 1615 • ACR Convergence 2025
Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Anushri Nimbvikar¹, Eleftherios Mylonakis² and Anthony M. Reginato³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, ²Department of Medicine, Houston Methodist Hospital, Houston, ³Brown University, Providence, RI
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive autoinflammatory disorder first identified in 2014. Four major disease phenotypes have been described:…
Abstract Number: 1152 • ACR Convergence 2025
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
Claudia Campos-Fabre¹, Carlota Ureta-Moneva¹, Elena Sendagorta¹, Jose Rodríguez-Gago¹, Maria José Beato¹, Agustin Remesal², Rosa Alcobendas¹, Clara Udaondo¹, Gema Bonilla³, Laura Nuño⁴, Irene Monjo Henry², Carolina Tornero⁵ and Chamaida Plasencia-Rodríguez², ¹La Paz University Hospital, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁵Hospital La Paz, Madrid, Spain
Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…
Abstract Number: 0250 • ACR Convergence 2025
Autoinflammatory diseases in adult patients. Spanish registry.
Eztizen Labrador-Sanchez¹, Diana Prieto-Peña², Carlota L Iñiguez³, Rafael B. Melero-González⁴, Alberto Ruiz-Roman⁵, Clara Moriano⁶, Paula García-Escudero⁷, Anahy Maria Brandy⁸, Marta López⁹, Fred Anton Pages¹⁰, Maria Camila Osorio-SanJuan¹¹, Nahia Plaza-Aulestia¹², Bryan Josué Flores Robles¹³, Estibaliz Andres Trashaedo¹⁴ and Ricardo Blanco¹⁵, ¹Hospital Universitario San Pedro, Laguardia, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ³Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ⁴COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁵Hospital Juan Ramon Jimenez, Huelva, Spain, ⁶Hospital León, LEON, Castilla y Leon, Spain, ⁷Hospital Universitario Álava, Bilbao, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁰Hospital General de Segovia, Segovia, Spain, ¹¹Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹²Rheumatology division. Galdakao-Usansolo University Hospital, Galdakao, Spain, ¹³Hospital San Pedro, Logroño, Spain, ¹⁴Hospital San Pedro, Logroño, Spain, ¹⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Autoinflammatory diseases(AIDs) are characterized by recurrent inflammatory episodes resulting from alterations in regulatory genes, activating the innate immune system. Although these diseases primarily occur…

« Previous Page
1
…
3
4
5
6
7
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].